Incyte Corporation
COMBINATION THERAPY COMPRISING AXL/MER AND PD-1/PD-L1 INHIBITORS
Last updated:
Abstract:
The present disclosure relates to methods of treating cancer by administering a compound, which is an AXL/MER kinase inhibitor, in combination with an antibody, or an antibody fragment thereof, that binds to PD-1.
Status:
Application
Type:
Utility
Filling date:
5 Mar 2021
Issue date:
9 Sep 2021